Indian Journal of Endocrinology and Metabolism最新文献

{"title":"Relationship of Recurrence Rate with some Characteristics in Patients with Thyroid Carcinoma.","authors":"Bui D M Tri, Bui D P Chi, Bui T Hiep, Nguyen H Trung, Tong D Minh, Nguyen T N Dung, Thanh D Bui, Viet Q Tran, Hiep T Nguyen","doi":"10.4103/ijem.ijem_134_23","DOIUrl":"10.4103/ijem.ijem_134_23","url":null,"abstract":"<p><strong>Background: </strong>Determining the clinical and subclinical characteristics related to the recurrence status in patients with a thyroid carcinoma has great significance for prognosis, prediction of recurrence and monitoring of treatment outcomes. This study aimed to determine the association between recurrence rate and some characteristics in patients with thyroid carcinoma.</p><p><strong>Patients and methods: </strong>The study was conducted by descriptive method with longitudinal follow-up on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam, from July 2013 to December 2016.</p><p><strong>Results: </strong>Univariate analysis showed that there was a relationship between the recurrence characteristics in the studied patients and the characteristics of lymph node metastasis (<i>P</i> = 0.026; OR = 15; 95% CI = 1.4-163.2) and BRAF V600E mutation status (<i>P</i> = 0.01; OR = 3.41; 95% CI = 1.31-8.88). When analysing the multivariable Logistic regression model, there was a positive correlation between the occurrence of BRAF V600E gene mutation (<i>P</i> = 0.032; OR = 17.649; 95% CI = 1.290-241.523) and male sex (<i>P</i> = 0.036; OR = 12.788; 95% CI = 1.185-137.961) and the occurrence of recurrence in study patients. The mean time to relapse was earlier in male patients than in female patients (<i>P</i> = 0.02). The mean time to relapse in patients with the BRAF V600E mutation (31.81 ± 1.14 months) was shorter than the mean time to relapse in the group without the mutation (57.82 ± 2.08 months) (<i>P</i> = 0.01). The group of patients with mutations in the BRAF V600E gene increased the risk of recurrence compared with the group without the mutation (HR = 9.14, <i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>There is a positive correlation between recurrence and masculinity, lymph node metastasis and the occurrence of BRAF V600E mutations in thyroid carcinoma patients.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"544-551"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Integrated Clinical Score to Predict Remission in Cushing's Disease.","authors":"Nidhi Gupta, Aditya Dutta, Mintu Mani Baruah, Anil Bhansali, Chirag Kamal Ahuja, Sivashanmugam Dhandapani, Sanjay Kumar Bhadada, Uma Nahar Saikia, Rama Walia","doi":"10.4103/ijem.ijem_314_23","DOIUrl":"10.4103/ijem.ijem_314_23","url":null,"abstract":"<p><strong>Objective: </strong>To derive a clinical score from parameters that favor remission of Cushing's disease (CD) after pituitary surgery.</p><p><strong>Methods: </strong>This is an analysis of 11 clinical, hormonal, and post-operative parameters that each favored remission in a cohort of 145 patients with CD treated by trans-sphenoidal surgery (TSS). Each parameter was designated as a categorical variable (presence/absence), and several favorable parameters present for each patient were calculated. From this, a median parameter score (clinical score) of the entire cohort was derived, which was then compared to the event of remission/persistence of CD.</p><p><strong>Results: </strong>The median number of favorable parameters present in the entire cohort was 3 (0-7). The significant count of patients in remission increased with the increasing number of parameters. The receiver-operator characteristic curve showed that the presence of ≥3 parameters was associated with remission in CD with a sensitivity of 84.2% and a specificity of 80%. Patients with a clinical score ≥3 had significantly higher remission rates (88.9%) than those who had persistent disease (27.3%; <i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>A clinical score of ≥3 predicts remission in CD treated by TSS; however, it requires validation in other large cohorts. Rather than assessing individual parameters to predict remission in CD, an integrated clinical score is a better tool for follow-up and patient counseling.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"501-505"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, Clinical Profile, and Analysis of Risk Factors in COVID Associated Rhino-orbito-cerebral Mucormycosis Patients - An Observational Study.","authors":"Komal Jog, Roshan Nazirudeen, Subbiah Eagappan, Raghavan K Santharam, Subbiah Sridhar","doi":"10.4103/ijem.ijem_372_22","DOIUrl":"10.4103/ijem.ijem_372_22","url":null,"abstract":"<p><strong>Aim of study: </strong>To study the clinico-epidemiological profile and identify risk factors for the development of COVID-19-associated mucormycosis (CAM) among the patients treated at our regional mucormycosis center.</p><p><strong>Materials and methods: </strong>This was a cross-sectional single-centre observational study. All CAM patients admitted to Government Rajaji Hospital, Madurai from April 2021- August 2021 were included in the study. Information regarding clinical features, potential risk factors, diagnostic workup, and comorbid illness was collected.</p><p><strong>Results: </strong>A total of 164 patients of CAM were admitted to our hospital with a mean age of 51.7 years. Out of 164 patients, 12 patients were not covid positive, based on imaging and RT-PCR, however subclinical infection could not be ruled out. Out of the 164 patients studied, 160 patients had diabetes, out of which 66% (n = 105) patients had a previous history of diabetes, and 34% (n = 55) had newly detected diabetes. Most of the patients admitted with mucormycosis had uncontrolled diabetes (94%) and were not on insulin therapy, but were on oral antidiabetic drugs alone. The majority of the patients (68%) have received steroids (IV/oral) during the COVID-19 illness. 74% of these patients were under hospitalization for COVID-19 disease. Only 30% (n = 50) of CAM patients had a history of oxygen therapy and 7% of these patients were treated in ICU during active COVID-19 illness. 59% of patients used cloth masks without adequate hygiene, rest 41% (n = 67) patients reused disposable masks. We also found that 87% of the patients developing mucormycosis had exposure to organic material in the convalescence period of COVID-19 illness.</p><p><strong>Conclusions: </strong>From our study, we found steroid use, poorly controlled diabetes mellitus, reuse of masks, daily steam inhalation, and exposure to organic matter to be more associated with CAM, but oxygen therapy was less associated with CAM. Hence, we could suggest screening for hyperglycemia and daily use of disposable surgical masks to be continued for at least 4 weeks post-COVID-19. It is preferable to continue insulin in titrated doses along with OHA for at least 4 weeks following steroid cessation in the post-COVID-19 period as there is are considerably increased inflammatory cytokine levels in the convalescence phase. Clean environmental hygiene would also help prevent CAM.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"519-523"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Landscape of Diabetes Epidemic in Southeast Asia: Insights from National Family Health Survey.","authors":"Rahul Gupta, Aashish Upadhyay, Shweta Kohli, Rajesh Khadgwat","doi":"10.4103/ijem.ijem_215_23","DOIUrl":"10.4103/ijem.ijem_215_23","url":null,"abstract":"<p><strong>Background: </strong>Limited evidence on diabetes prevalence trends from the Indian subcontinent prompted this study to estimate the trends in diabetes prevalence using the National Family Health Survey (NFHS) data.</p><p><strong>Method: </strong>A cross-sectional survey carried out between 2015-2016 (NFHS-4) and 2019-2021 (NFHS-5) in a nationally representative sample of adults (aged 20 to 54 years) was used. Diabetes was defined as the presence of: diagnosed diabetes (self-reported), fasting plasma glucose (FPG) ≥ 126 mg/dl, or a random plasma glucose (RPG) ≥200 mg/dl. \"Fasting\" was defined as the last food intake >8 hours and \"random\" as irrespective of the last meal. Diagnosed diabetes was defined as the presence of \"self-reported diabetes\" and undiagnosed diabetes was defined as FPG > 126 mg/dl or RPG ≥200 mg/dl.</p><p><strong>Findings: </strong>The crude prevalence of total diabetes increased from 3.5% (95% confidence interval (CI): 3.46-3.55) in 2015-2016 to 3.99% (95% CI: 3.94-4.04) in 2019-2021, a relative change of 14%. The increase was more in the poorest (1.77% vs 2.48%; <i>P</i> < 0.001) as compared to the rich (5.35%% vs· 5.43%; <i>P</i> = 0.847), rural areas (2.71% vs 3.38%; <i>P</i> < 0.001) as compared to urban (4.95% vs. 5.26%; <i>P</i> = 0.051), in normal weight individuals (1.87% vs. 2.16%; <i>P</i> < 0.001) as compared to obese (7.12% vs. 7.03%; <i>P</i> = 0.384).</p><p><strong>Interpretation: </strong>While the absolute prevalence of diabetes is highest amongst individuals residing in urban areas belonging to the rich wealth centile, the relative increase in the prevalence is disproportionately higher in those residing in rural areas, belonging to the poorest wealth centiles and having normal weight.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"492-500"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemorrhagic Rathkes Cleft Cyst Apoplexy Post COVID-19 Vaccination.","authors":"Tarang K Vora, Rahul Lath, Meenakshi Swain, Amitava Ray","doi":"10.4103/ijem.ijem_381_23","DOIUrl":"10.4103/ijem.ijem_381_23","url":null,"abstract":"","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"567-569"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociocrinology: Impact of Social Media on Endocrine Health - A Review.","authors":"Jaideep Khare, Sanjay Kalra, Sushil Jindal","doi":"10.4103/ijem.ijem_250_23","DOIUrl":"10.4103/ijem.ijem_250_23","url":null,"abstract":"<p><p>Social media (SM) refers to social networking sites (SNSs), which are defined as online services that enable individuals to build a public or semi-public profile and give them the opportunity to create a network of contacts and interact. SM affects all aspects of life and may offer new opportunities to explore new experiences and perspectives of life because of its feasibility. But several times, because of feasibility, misinformation is generated intentionally or unintentionally, which spreads rapidly, and such misinformation can affect all aspects of life. However, health-related misinformation can be life-threatening to individuals. Endocrinology is the branch of medicine that deals with endocrine glands and hormones, which regulates mood, growth, development, metabolism and the way our organ works to maintain internal homeostasis. SM usage and endocrine health impact each other in both positive and negative ways. So, in this review, we will discuss about the effect of SM on Endocrine health.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"480-485"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139901124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Prostate Cancer in Transgender Women Undergoing Androgen Deprivation Therapy: A Review.","authors":"Saurabh Tyagi, Surbhi Tyagi","doi":"10.4103/ijem.ijem_53_23","DOIUrl":"10.4103/ijem.ijem_53_23","url":null,"abstract":"<p><p>Transwomen frequently undergo androgen deprivation therapy (ADT) incorporated with oestrogen, but they are still prone to the occurrence of prostatic cancer since the prostate remains intact. The probability of this clinical condition reduces as compared with the general male population. This study aimed to study the occurrence of prostatic malignancy under hormonal therapy such as ADT in transwomen. An extensive literature search was performed using online searches on transgender health, centring on the incidence, diagnosis, treatment and management of prostate cancer in transgender women. Original articles from 1975 to 2022 were searched using PubMed, Scopus, EMBASE, DOAJ and Cochrane databases. Physical, mental and communal deliberation of health development is the major constituent of trans-health. It exhibits a fivefold reduction in prostatic malignancies in transwomen undergoing hormonal therapy contrasted with the extensive male community of indistinguishable age.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"476-479"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 Vaccination and Thyrotoxicosis (ASIA Syndrome): Single-Centre Experience from India with Review of Literature.","authors":"Vaibhav Singhal, Sushil Gupta","doi":"10.4103/ijem.ijem_202_23","DOIUrl":"10.4103/ijem.ijem_202_23","url":null,"abstract":"<p><strong>Introduction: </strong>Thyrotoxicosis is not uncommon after immunization. It is known as 'autoimmune/autoinflammatory syndrome by adjuvants (ASIA syndrome)' and is caused by immunological reaction to adjuvants. However, there is insufficient information on thyrotoxicosis after COVID-19 vaccination in the Indian subcontinent.</p><p><strong>Aims/objectives: </strong>To investigate the spectrum of thyrotoxicosis after COVID-19 immunization.</p><p><strong>Settings and design: </strong>A single-centre retrospective study was conducted at a tertiary care academic institute in India.</p><p><strong>Materials and methods: </strong>We studied the clinical symptoms, biochemical markers, imaging characteristics and treatment of every patient who was diagnosed with thyrotoxicosis within 60 days of receiving the COVID-19 vaccine.</p><p><strong>Results: </strong>Following COVID-19 vaccination, we diagnosed ten people (mean age 39.9 years, range 22-63 years) with thyrotoxicosis [Graves' disease (GD, <i>n</i>-6) and subacute thyroiditis (SAT, <i>n</i>-4)]. The typical duration for symptoms to appear was 2 to 60 days. The majority of patients (<i>n</i>-9) received the COVISHIELD™ vaccine, whereas only one received the COVAXIN^® vaccine. After vaccination, two patients with GD developed mildly severe Graves' orbitopathy, with symptoms emerging two days and sixty days later, respectively. Anti-thyroid drugs (methimazole or carbimazole) were required for all GD patients. All SAT patients were treated conservatively with nonsteroidal anti-inflammatory medications and had positive outcomes.</p><p><strong>Conclusions: </strong>SAT, GD and GO may occur as a manifestation of ASIA syndrome, following immunization with COVISHIELD™ and COVAXIN^®. Despite the obvious benefits of the COVID-19 vaccine, clinicians should be aware of any potential autoimmune and inflammatory thyroid problems.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"524-529"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Zoledronic Acid in Hepatic Osteodystrophy: A Double-Blinded Placebo-Controlled Trial.","authors":"Henith Raj, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Pazhanivel Mohan, Krishnan Nagarajan, Sagili V B Reddy, Harsh Durgia, Rajan Palui","doi":"10.4103/ijem.ijem_233_23","DOIUrl":"10.4103/ijem.ijem_233_23","url":null,"abstract":"<p><strong>Purpose: </strong>Literature on the treatment of pre-transplant hepatic osteodystrophy (HOD) is limited. The general treatment measures and their timing are currently adopted from the literature on postmenopausal osteoporosis. Therefore, we conducted this randomized study to investigate the effect of zoledronic acid (ZA) on HOD.</p><p><strong>Methods: </strong>We randomized 36 male patients with cirrhosis (Child-Pugh class A and B) into 19 to the ZA arm and 17 to the placebo arm, respectively. Patients in the ZA arm received a single infusion of 4 mg ZA dissolved in 100 mL of normal saline at baseline, while patients in the placebo arm received a similar infusion of normal saline at baseline. The primary outcome of the study was the change in lumbar spine bone mineral density (LS-BMD) at 12 months.</p><p><strong>Results: </strong>Of 36 patients, 28 completed the study (15 in the ZA arm and 13 in the placebo arm). The mean increase in LS-BMD (g/cm²) in the ZA and placebo arms was 5.11% (3.50) and 0.72% (4.63) [<i>P</i> = 0.008], respectively. The trabecular bone score (TBS) did not improve significantly in either arm. The incidence of vertebral fractures (VFs) was similar in both arms. There was a significant decrease in plasma beta-C-terminal telopeptide (β-CTX) levels in the ZA arm compared to the placebo arm, while the change in plasma levels of procollagen 1 intact N-terminal propeptide (P1NP) was similar in both arms. Six patients (31.6%) in the ZA arm experienced adverse reactions such as fever and myalgia.</p><p><strong>Conclusion: </strong>ZA improved LS-BMD in male patients with HOD by decreasing bone resorption. However, it may not improve trabecular microarchitecture or prevent morphometric VFs in this population.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"552-558"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of Effects of Gender-Affirming Hormone Therapy on Bone Mineral Density in Individuals with Gender Dysphoria.","authors":"Rakesh Bobba, Pramila Kalra, Mala Dharmalingam","doi":"10.4103/ijem.ijem_265_23","DOIUrl":"10.4103/ijem.ijem_265_23","url":null,"abstract":"<p><strong>Introduction: </strong>Gender affirming hormone therapy (GAHT) is the mainstay treatment in transitioning individuals and has positive physical and psychological effects. Among the things to monitor in transgender patients on long-term hormones, bone health is an essential consideration. As the calcium intake in the Indian population is less, and many gender-incongruent individuals may not take adequate calcium in their diet, we needed data on the bone health of Indians with gender dysphoria as the information available globally may not apply to our population.</p><p><strong>Materials and methods: </strong>The study was performed to assess bone mineral density in individuals with gender dysphoria who were on gender-affirming hormonal therapy for at least 6 months. It was a hospital-based cross-sectional study of bone mineral density measured at two sites - hip and spine in individuals with gender dysphoria on GAHT for at least six months.</p><p><strong>Results: </strong>A total of 30 individuals were included in this study. The mean age of individuals with Gender dysphoria was found to be 28.17 ± 6.15 years, and the age range was 19-42 years. Out of the 30 individuals, 14 were transgender males, and the remaining 16 were transgender females. Bone mineral density at the hip and spine in transgender males was 1.047 ± 0.124 g/cm² and 1.065 ± 0.115 g/cm², which was better compared to transgender females in whom the bone mineral density at hip and spine was 0.899 ± 0.873 g/cm² and 0.854 ± 0.099 g/cm² (<i>P</i> = 0.001 for hip; <i>P</i> = 0.000 for spine). The Z score at hip and spine were better in transgender males as compared to transgender females (<i>P</i> < 0.001 for hip; <i>P</i> < 0.001 for spine) when compared to genetic sex and at the spine (<i>P</i> = 0.001) when compared to affirmed sex. In this study, we observed that the transgender females who underwent orchidectomy had a lower mean Z score at spine compared to individuals who did not undergo the procedure.</p><p><strong>Conclusions: </strong>The current study results indicate that GAHT does have positive effects on bone health in transmen.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"27 6","pages":"486-491"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}